Seattle Children’s Hospital

Solid Tumor Immunotherapy Clinical Trial Strive-02

$100,000 in new funds ($50,000 donation, plus $50,000 MacDonald match) would cover research-related costs for the first 10 patients enrolled in this innovative treatment.

Community support is moving ahead new T-cell clinical trials in our pipeline that will bring hope to children fighting many kinds of cancer. You can help us develop these studies more quickly. Donors that wish to, may direct their support to a specific T-cell trial being developed at the Ben Towne Center for Childhood Cancer Research.  The Solid Tumor Immunotherapy Clinical Trials fund is the top priority for Dr. Julie Park and Dr. Navin Pinto, providing resources to develop the STRIvE-02 phase I clinical trial for children with relapsed or refractory solid tumors outside of the brain.  The chimeric antigen receptor (CAR) T cells developed for the STRIvE-02 trial will target the B7-H3 molecule which is present on the surface of many childhood solid tumors including neuroblastoma and a variety of sarcomas.

High-Risk Leukemia Clinical Trials Fund

$120,000 – will both pay for average cost of genetic sequencing and fill the gap between federal funding and actual cost of clinical trial participation for up to 10 HRL patients.

This fund is the top priority for Dr. Todd Cooper, director of the Pediatric Leukemia/Lymphoma Program, Evans Family Endowed Chair in Pediatric Cancer, and co-director of the integrated High-Risk Leukemia Program at Seattle Children’s.  The first-of-its-kindHigh Risk-Leukemia Program greatly improves the experience of patient families, who meet with all the experts involved in their child’s care at one time.  Those in-take meetings bring together care-providers from multiple institutions including transplant teams and lab researchers who provide genetic sequencing information to ensure the best match between each child and the most promising clinical trial for his or her leukemia.  This fund supports the cost of those clinical trials, as well as the necessary genetic testing, thus helping improve outcomes for kids. Genetic testing costs on average $5,000 per patient and is rarely covered by insurance.  The gap between federal funding and the actual cost of participation for each child enrolled in a clinical trial varies but is typically at least $7,000 for high-risk leukemia (HRL) trials – note this is higher cost than the general average for all cancer trials. In 2019, our High-Risk Leukemia team anticipates treating 30 patients in Seattle and providing remote consultations for up to 40 additional patients.

In honor of Cecile, Ian, Hanna, and Jack.

Children’s Circle of Care $10,000 Donation! Seattle Children’s Cancer Clinical Trials Fund
This fund is the top priority for Dr. Doug Hawkins who leads our Cancer and Blood Disorders unit. This fund helps cover the cost of studies for all types of cancer — so every child can benefit from the best therapies available. These trials impact hundreds of kids annually. In 2016, our oncology team ran 101 cancer research studies, with 899 enrollments (some patients enrolled in more than one study). Thanks to these clinical trials, and the donors who support them, survival rates as Seattle Children’s surpass the national average for nearly every type of cancer. Many of the promising cancer studies highlighted in our publications are supported by this fund. One recent example is a sarcoma study led by Dr. Hawkins and one of our new cancer team members Dr. Katie Albert. This blog post details the experience of one 5-year-old patient in the study whose tumor has disappeared entirely. The fund also supports a lot of other groundbreaking research, including Dr. Sarah Leary’s exciting Tumor Paint trial.

The Cancer Center at Valley Medical Center / UW Medicine

Valley Girls & Guys Donation of $500,000 for Valley Medical Cancer Center

The Cancer Center at Valley Medical

Valley Girls & Guys! pledged $500,000 to Valley Medical Center/UW Medicine’s new cancer Center over the next 5 years (starting in 2018) to help fund new equipment such as the SaviScout, HDR (High Dose Radiation) Machine, Clinical Remote Conferencing system for the MDC and a brand new HOPE (Helping Oncology Patients with Everything) Patient Assistance Fund.  This will Save Lives.

ACUTE CARE SERVICE FOR ALL TYPES OF CANCERS

$120,000 IN NEW FUNDS WILL OPEN THE FIRST EVER ACUTE CARE SERVICE FACILITY FOR ALL CANCER PATIENTS IN THE FALL OF 2020. The funding will fill the gap between now and then and allow us to offer this service to cancer patients immediately. The providers would like to offer an Acute Care service established specifically for evaluation and acute symptom management for cancer patients. This is for people undergoing chemo and radiation who need management of severe symptoms that normally requires intervention in the Emergency Department. This would provide a more supportive, less stressful and more sterile environment designed to meet the special needs of cancer patients.

UW Medicine Cancer Vaccine Institute

ADDRESSING THE RETURN OF OVARIAN CANCER

$120,000 in new funds pays for the generation of a master cell bank which is a cassette that can be used again and again to produce more vaccine. The next step is the vaccine production. The GMP laboratory at the FHCRC uses the cassette to generate a batch of the vaccine in large vats. Once the vaccine is made, it is purified over a column, and then put into vials for use. The ovarian cancer vaccine would need to go through this entire process.

Ovarian cancer is treatable the first time it appears. Unfortunately, it is deadly if it returns, which occurs in most cases (over 70%). CVI researchers have developed a multi-antigen vaccine targeting key proteins that initiate metastatic ovarian cancer. CVI researchers now want to manufacture the vaccine and conduct a “first in women” study to test the safety of the vaccine and whether it can generate high levels of immunity against ovarian cancer. If successful, the next step would be a trial to see if the vaccine can prevent ovarian cancer from coming back after treatment.
Update (August 2019)

We have manufactured to the vaccine in the laboratory and are now in the process of performing tests to determine whether the vaccine can undergo “scale up” manufacturing to create enough to conduct a clinical trial and we are determining whether vaccination of specific cell lines produced high enough levels of protein to be able to stimulate an immune response. These studies are part of those required to submit an “Investigational New Drug” application to the US Food and Drug Administration which is one of the first hurdles we need to pass to start a clinical trial.

TARGETING INVASIVE BREAST CANCER WITH A MULTI-ANTIGEN VACCINE

$60,000 in new funds will be used to use the master cell cassette and make the first batch of vaccines for trial.
Researchers at the UW Medicine Cancer Vaccine Institute (CVI) have identified proteins present in breast cancer stem cells that cause invasive breast cancer. The CVI has created a multi-antigen vaccine targeting five of these proteins. Now CVI researchers would like to manufacture a new lot of vaccine and test vaccine in combination with chemotherapy in women with “locally advanced breast cancer”. This is breast cancer that is too big to be taken out by surgery and women must have chemotherapy before the surgery. The Phase II clinical trial would be designed to see if vaccination can increase the number of immune cells in the tumor and whether vaccines will enhance the destruction of the tumor resulting in eradication of the tumor prior to surgery. This study will set the stage for larger trials to see if the vaccine added to chemotherapy is better than chemotherapy alone.
Update (August 2019)

We have begun working on the design of the clinical protocol, the choice of the patient population, and the types of biomarkers we will use in the study proposed. We have recently identified a more efficient method to vaccinate patients with breast cancer using a small electrical impulse to the skin at the time the vaccine is given. This method is called “electroporation” and is particularly well suited to our vaccine which uses DNA to immunize. We are planning on starting a Phase II trial of testing electroporation in patients similar to those we enrolled on our initial study. If this new method is superior in stimulating higher levels of immunity to these breast cancer proteins we will take this method forward into our therapeutic trial-the one designed to generate anti-tumor responses.

Camp Kesem at University of Washington

Valley Girls & Guys Donation of $500,000 for Valley Medical Cancer Center

Sending Kids to Camp Kesem

Valley Girls & Guys has donated $33,985.00 to send 70 kids (ages 6 through 16) to Camp Kesem for one week Summer Camp last year and this year.  This is a fantastic organization that helps children get through the trauma and pain of seeing a parent or loved one go through cancer treatments or losing the battle with cancer.  We will continue to raise funds in partnership with Camp Kesem at University of Washington to help send more children to Camp Kesem in the future.

Casting for Recovery® (CfR)

Casting for Recovery logo - dedicated to supporting breast cancer patients through sport fly fishing
Casting for Recovery in group with their fishing gear on ready to go fly fishing with breast cancer patients

Sending Kids to Camp Kesem

Valley Girls & Guys has committed to gifting $12,000 in funds to Casting for Recovery dedicated to this year’s retreat and for a second retreat in 2021! They believe in our mission and heard our desire to serve more breast cancer survivors.

CrR mission is to enhance the quality of life of women with breast cancer through a unique retreat program that combines breast cancer education and peer support with the therapeutic sport of fly fishing. The program offers opportunities for women to find inspiration, discover renewed energy for life and experience healing connections with other women and nature. CfR serves women of all ages, in all stages of breast cancer treatment and recovery, at no cost to participants.

Accomplishments

  • 16 mammograms, ultrasounds, and biopsies funded for those who have no insurance, a high insurance deductible or the financial means to pay for one.

  • 1600+ Blankets mailed/delivered all over the world to all cancer patients.
  • 9 Scholarships awarded to graduating seniors going to college that have been affected by cancer in their families = $22,500.00.  We are now expanding our High school senior scholarship program in 2020.  Aside from the (2) $2500 scholarships to Tahoma High School we will now be offering (1) $2500 to Enumclaw High School and (4) to the Kent School District High schools (Kentridge, Kentlake, Kentwood, Kent-Meridian).

  • 70 Kids attended Camp Kesem Summer Camp

  • 7 Who Dreams for individuals terminal with cancer.

  • 3.2+ Million dollars raised for Susan G. Komen for the Cure to fund research, grants, education, mammograms and more!

  • 1,088 patients benefitted from the Valley Girls & Guys! HOPE Patient Assistance Funds, support groups, cards of inspiration, and Savi scout in 2018 at Valley Medical Center/Uw Medicine.

  • $36,800.00 donated to Valley Medical Center/UW Medicine to the Patient Assistance Fund 2018/2019 in addition to our original pledge.

  • $9,775 donated  to Valley Medical Center/ Uw Medicine to assist with equipment in addition to our original pledge.

  • $41,400 donated to Seattle Children’s Cancer Clinical Trials Fund (fills the gap between federal funding and actual cost for wide range of cancer clinical trials) in addition to our original pledge.

  • $5,750 donated to Seattle Children’s Strive 02 Clinical Trial in addition to our original pledge.

  • HOPE in your Heart Cancer Support Groups began in January of 2019 in Maple Valley, last Monday of the month.  A place where you can meet others who understand the journey of cancer.  Share ideas, resources, and challenges.  Through open discussion and presentations get the support you and your loved one need.
  • $10,000 donated to Children’s Circle of Care in 2019 in addition to our original pledge in 2018.